Molecular Formula | C12H10O7V |
Molar Mass | 317.15 |
Melting Point | >300°C (dec.) |
Water Solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
Solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
Appearance | Morphological powder color yellow to gray to brown |
Color | yellow to grey to brown |
Storage Condition | Refrigerator |
In vitro study | Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells. |
In vivo study | Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice. Animal Model: C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) Dosage: 0.75-3.0 mmol Administration: Intraperitoneal injection; twice weekly; for 6 weeks Result: Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |
UN IDs | UN 2811 6.1 / PGIII |
WGK Germany | 3 |
Biological activity
BMOV (Bis maltolato oxovanadium, Bis(maltolato)oxovanadium (IV)) is an effective oral vanadium complex with anti-diabetic properties and insulin-mimicking effects. BMOV has been shown to improve cardiac dysfunction in diabetic models.
Target
IC50: 126 nM (HCPTPA), 109 nM (PTP1B), 26 nM (HPTPβ) and 201 nM (SHP2)
biological activity | BMOV (Bis maltolato oxovanadium, Bis(maltolato)oxovanadium (IV)) is an effective oral vanadium complex with anti-diabetic properties and imitation The effect of insulin. BMOV has been shown to improve cardiac dysfunction in diabetic models. |
target | IC50: 126 nM (HCPTPA), 109 nM (PTP1B), 26 nM (HPTPβ) and 201 nM (SHP2) |
in vitro study | Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells. |
in vivo study | Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J ice) treatment ameliorates the metabolic phenotype. Living, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analyzed tissues compared to HFD mice. Animal Model: C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) Dosage: 0.75-3.0 mmol Administration: Intraperitoneal injection; twice weekly; For 6 weeks result: Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |
Animal Model: | C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) |
Dosage: | 0.75-3.0 mmol |
Administration: | Intraperitoneal injection; twice weekly; for 6 weeks |
Result: | Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |